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Abstract
Background: Experimental models are necessary to elucidate diabetes pathophysiological mechanisms not yet 
understood in humans. Objective: To evaluate the repercussions of the mild diabetes, considering two methodologies, 
on the pregnancy of Wistar rats and on the development of their offspring.
Methods: In the 1st induction, female offspring were distributed into two experimental groups: Group streptozotocin 
(STZ, n = 67): received the β-cytotoxic agent (100 mg STZ/kg body weight - sc) on the 1st day of the life; and Non-
diabetic Group (ND, n = 14): received the vehicle in a similar time period. In the adult life, the animals were mated. After 
a positive diagnosis of pregnancy (0), female rats from group STZ presenting with lower glycemia than 120 mg/dL 
received more 20 mg STZ/kg (ip) at day 7 of pregnancy (2nd induction). The female rats with glycemia higher than 120 
mg/dL were discarded because they reproduced results already found in the literature. In the mornings of days 0, 7, 14 
and 21 of the pregnancy glycemia was determined. At day 21 of pregnancy (at term), the female rats were anesthetized 
and killed for maternal reproductive performance and fetal development analysis. The data were analyzed using 
Student-Newman-Keuls, Chi-square and Zero-inflated Poisson (ZIP) Tests (p < 0.05).
Results: STZ rats presented increased rates of pre (STZ = 22.0%; ND = 5.1%) and post-implantation losses (STZ = 26.1%; 
ND = 5.7%), reduced rates of fetuses with appropriate weight for gestational age (STZ = 66%; ND = 93%) and reduced 
degree of development (ossification sites).
Conclusion: Mild diabetes led a negative impact on maternal reproductive performance and caused intrauterine 
growth restriction and impaired fetal development.
Background
Diabetes mellitus (DM) is characterized by disarrange-
ment of the metabolism of carbohydrates, proteins and
lipids caused by the complete or relative insufficiency of
insulin secretion and/or insulin action [1]. DM is not a
disease but rather a heterogeneous group of syndromes
characterized by elevated glucose levels caused by the
absolute or relative deficiency of insulin. DM can be clas-
sified into: type-1 diabetes (DM1), type-2 diabetes (DM2)
and gestational diabetes (DMG). DM1 mainly affects
children and young people and results in the destruction
of beta (β)-pancreas cells due to autoimmune processes.
DM2 refers to the reduction of endogenous insulin in tar-
get tissues, particularly liver, muscle and adipose tissue,
with relative insulin deficiency. DMG is characterized by
the establishment of glucose intolerance, first being iden-
tified between 24-26 weeks of pregnancy. DMG may per-
sist after birth and progress to DM2 [1,2].
Pregnancy is characterized by insulin resistance and
compensatory hyperinsulinemia and is a period when
maternal pancreatic functional reserve is tested. In the
absence of pancreatic functional reserve, the pancreas
fails to produce insulin levels with relative hypoinsulin-
ism in the second half of pregnancy with consequent
maternal hyperglycemia, characterizing DMG [3]. The
pathophysiology of DMG is not fully elucidated. Its inci-
d e n c e  i s  v a r i a b l e  a n d  o c c u r s  i n  3  t o  8 %  o f  p r e g n a n t
women [4,5].
Impaired reproductive performance is a well-known
result of the diabetic syndrome in many mammalian spe-
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cies, including humans. Depending on the severity of the
diabetes, pregnancy is frequently impaired. Anovulation,
alteration in the estral cycle, reduction in follicular
recruitment, insensitivity to exogenous gonadotrophin
therapy, steroidogenesis depression and ovarian atrophy
are associated with the diabetic state [6,7].
Women with disorders of glucose tolerance present
with increased maternal and perinatal morbidity [8], such
as spontaneous miscarriages and neonatal morbidity and
mortality [9-11]. Improvement in glycemic control dur-
ing gestation reduces the incidence of spontaneous mis-
carriages and congenital malformations in the offspring
of diabetic women [12].
Epidemiological studies in humans and in experimental
animals have shown that offspring of women/rats with
gestational/mild diabetes were born macrosomic and
developed glucose intolerance during adulthood. There-
fore, there is a diabetogenic tendency between different
generations in terms of an unfavorable intrauterine envi-
ronment. This trend was confirmed by experimental tests
and studies of human populations, which revealed that
inheritance of diabetes is more influenced by maternal
than by paternal diabetes [13-15].
Studies in humans that explore the responsible mecha-
nisms for alterations caused by diabetes in pregnancy are
limited not only by ethical reasons but also by the multi-
plicity of uncontrolled variables that may modify the
intrauterine environment [16]. Thus, there is a need for
appropriate animal models for a better understanding of
the diagnosis, pathophysiology and treatment of diabetes.
In order to reproduce the clinical conditions of poorly
controlled type-1 diabetes, experimental models are used
to produce severe diabetes (glycemia>300 mg/dL) [17-
21]. The complications caused in the maternal and fetal
organism by severe diabetes are well-known. Addition-
ally, there are models that have been developed to repro-
duce the clinical conditions of type-2 and gestational
diabetes. In laboratory animals, these are classified as
mild diabetes (glycemia between 120 and 300 mg/dL).
Models of mild diabetes may be induced by administra-
tion of different doses of streptozotocin during the neo-
natal period [22-26] or by injection of streptozotocin
during pregnancy [16,27-31]. Sinzato [32] verified that
mild diabetes, induced in the neonatal period in female
Wistar rats, altered maternal glycemia in the beginning of
pregnancy, that caused alterations in the maternal organ-
ism and/or in the initial development of the embryo,
affecting its implantation and future placental and fetal
development. Spada [33], using the same female rats as in
the work of Sinzato [32], observed an increase in the
activities of glutathione peroxidase in erythrocytes and of
catalase in the placenta, demonstrating that the increase
of those biomarkers was enough to contain the possible
oxidative stress existent after marked hyperglycemia. Kiss
[ 3 4 ]  o bs e rv ed  t h a t  f e m a l e  r a ts  wi t h  m i l d  d ia be t e s  p r e -
sented with glucose intolerance in the period corre-
sponding to the emergence of gestational diabetes in
women. Morceli [35], using a different model of mild dia-
betes induction (administration of STZ in the neonatal
period and in pregnancy), verified that diabetic female
rats presented alteration in offspring weight and in the
percentage of pre and post-embryonic implantation
losses. However , only 48% to 60% of rats with diabetes
induced during neonatal or pregnancy period presented
with glycemia between 120 and 300 mg/dL, and the
results obtained are controversial regarding the presence
of fetal macrosomia and placental weight. Additionally,
there are no results concerning the effects of mild diabe-
tes on reproductive performance and placental and fetal
development. Therefore, the objective of the present
study was to evaluate the repercussions of the diabetes,
considering two methodologies, on the pregnancy of
Wistar rats and on the development of their offspring.
Methods
1. Animals and experimental groups
Newborn Wistar rats obtained from UNESP - Univ
Estadual Paulista, São Paulo State, Brazil were used. The
r a t s  w e r e  m a i n t a i n e d  i n  a n  e x p e r i m e n t a l  r o o m  u n d e r
controlled conditions of temperature (22 ± 2°C), humid-
ity (50 ± 10%), and a 12-hour light/dark cycle with ad libi-
tum access to commercial diet (Purina rat chow) and tap
water. On the day of birth, the rats were randomly distrib-
uted into two experimental groups: diabetic (STZ, n = 67)
and non-diabetic (ND, n = 14). Procedures and animal
handling were performed in accordance with the guide-
lines provided by the Brazilian College of Animal Experi-
mentation, and authorized by the Ethics Committee for
Animal Research of the São Paulo State University (Bra-
zil).
2. Experimental Sequence
The study was divided into four periods: diabetogenesis
1, mating, pregnancy and diabetogenesis 2. The experi-
mental model for diabetes and pregnancy was modified
from Calderon and colleagues [36] and the model of
induction of mild diabetes was adapted from the method-
ology described by Portha and colleagues [22] and Tsuji
and colleagues [26] (Figure 1).
2.1. Diabetogenesis period 1
Diabetes was induced on the first day of life by subcuta-
neous administration of streptozotocin (SIGMA Chemi-
cal Company, St. Louis, MO), at a dose of 100 mg/kg
diluted in 0.1 mol/L of citrate buffer (pH 4.5) [[22,26]
modified]. The ND rats received only citrate buffer. Fol-
lowing induction, the rats were kept with their dams with
a number of 8 newborns (one newborn/nipple, preferen-
tially females) during the lactation period (21 days). AtSaito et al. Diabetology & Metabolic Syndrome 2010, 2:26
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the end of this period, the dams were euthanized by car-
bon dioxide inhalation, and the offspring were main-
tained in the vivarium of the Laboratory of Experimental
Research on Gynecology and Obstetrics under controlled
conditions.
2.2. Mating period
At adult age (110 days of life), female rats were mated
with non-diabetic males. The morning when spermato-
zoa were found in the vaginal smear was designated ges-
tational day 0. The mating procedure consisted of 15
consecutive days, which comprises approximately three
estral cycles in order to obtain the appropriate sample
size in each group (n = 15). Non-mated female rats in this
period were considered infertile and excluded from the
study.
2.3. Pregnancy period
2.3.1. Glycemia During pregnancy, the females were
maintained in individual cages. In the mornings of days 0,
7, 14 and 21, glycemia was determined by a specific glu-
cosemeter (One Touch Ultra - Johnson & Johnson), and
the values were expressed in milligrams per deciliter (mg/
dL).
2.3.2. Diabetogenesis period 2 Rats from the STZ group
presenting with glycemia < 120 mg/dL at day 0 of preg-
nancy were included in this study and received another
dose of streptozotocin (20 mg/kg diluted in 0.1 mol/L of
citrate buffer, pH 4.5) at day 7 of pregnancy by intraperi-
toneal administration route. STZ rats presenting with
glycemia ≥120 mg/dL at day 0 of pregnancy were
excluded from this study, as because they reproduced
results already found in the literature and these animals
were used in another study in our lab. ND rats received a
similar volume of citrate buffer by the same route of
administration.
2.3.3. Maternal reproductive performance On day 21
of pregnancy, rats were anesthetized with sodium thio-
pental (Thiopentax - 50 mg/kg) and exsanguinated.
Maternal blood was stored in dry and heparinized tubes
for biochemical determinations. Laparotomy was then
performed to remove the uterine horns for weighing of
the litter and subsequent weighing of individual live
fetuses and placentas. The ovaries were also removed and
the corpora lutea counted and analyzed under a stereo-
microscope. The numbers of implantations, resorptions
(embryonic deaths), live and dead fetuses were counted as
well the rate of pre-implantation loss was calculated by
the following formula: number of corpora lutea - number
of implantation sites × 100/number of corpora lutea. The
rate of post-implantation loss was calculated by the fol-
lowing formula: number of implantations - number of
live fetuses × 100/number of implantations [37]. In the
absence of visible embryonic or fetal development, the
uterus was placed in reactive Salewski [38].
2.3.4. Insulin determination For measurement of insu-
lin concentration, blood samples collected in heparinized
tubes were centrifuged at 2500 × g and 4°C for 10 minutes
to obtain plasma and stored in a freezer at -80°C. Blood
from 15 rats (n = 7 for the ND group, n = 8 for STZ
group) was drawn to perform the measurement by ELISA
following the protocol of the manufacturer (Mercodia -
Rat Insulin).
2.3.5. Fetal classification Term fetuses were removed
and weighed. The fetuses were classified by the mean ±
1.7 SD according to the mean values of fetal weights of
the non-diabetic group (ND): as small for pregnancy age
(SPA) when weight was smaller than ND mean - 1.7 SD;
appropriate for pregnancy age (APA) when weight was
included in ND mean ± 1.7 SD; and large for pregnancy
age (LPA) when weight was greater than ND mean + 1.7
SD [31].
2.4. Analysis of fetal anomalies
The fetuses were weighed and analyzed for the presence
of external anomalies. After this analysis, half of the
fetuses were fixed in Bodian's solution and serial sections
were prepared as described by Wilson [39] for visceral
examination. The remaining fetuses were prepared for
skeletal examination by the staining procedure of Staples
& Schnell [40]. Besides the skeletal analyses, the counting
of the ossification sites was performed according to
methodology proposed by Aliverti [41], which deter-
mines the degree of fetal development.
3. Statistical analysis
The analysis of variance (ANOVA) was performed to
evaluate the main effects and interactions. For the pur-
poses of testing, the normality of the data was verified
and, when necessary, transformation was used. In the
case of significant difference, Student-Newman-Keuls
test was performed. For the classification of fetal weights
(SPA, APA, LPA), the Chi Square Test was performed to
compare distributions. For external and internal fetal
anomalies, Zero-inflated Poisson (ZIP) Test was applied.
A p-value of less than 0.05 was considered significant.
Figure 1 Experimental sequence.Saito et al. Diabetology & Metabolic Syndrome 2010, 2:26
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Results
1. Glycemia
Mean blood glucose concentration of rats during preg-
nancy is shown in Figure 2. In the beginning (day 0), at 7
and 21 days of pregnancy, maternal glucose levels did not
differ between experimental groups (p > 0.05). On the
14th day of pregnancy, there was an increase in mean glu-
cose in the STZ group.
2. Maternal reproductive performance and insulin 
determination
There were significantly decrease of full-term pregnant
rats in STZ group compared to the ND group. The STZ
group showed no significant difference in the mean num-
ber of live fetuses and fetal weight compared to the ND
group. Regarding maternal weight gain, number of cor-
pora lutea and implantations and percentage of losses pre
and post-implantation, the STZ group showed a
decreased incidence (p < 0.05) compared with ND group
(Table 1). At the end of pregnancy, the STZ group showed
no significant difference (p > 0.05) in insulin levels when
compared with ND group (Table 1).
3. Classification of fetal weights
The fetuses of rats in the ND group had appropriate
weights for age of pregnancy (APA - 93%). The remaining
fetuses were evenly distributed between small for preg-
nancy age (SPA - 3%) and large for pregnancy age (LPA -
3%). The STZ group, 66% of fetuses were classified as
APA, 26% as SPA and 8% as LPA. There was a significant
increase in SPA fetuses and reduction of APA fetuses (p <
0.05) in STZ group compared to ND group (Figure 3).
4. Analysis of fetal anomalies
4.1. Ossification sites
The fetuses from STZ rats showed a significant difference
in number of anterior and posterior phalanges, metatar-
sus and total ossification sites (p < 0.05) compared with
fetuses from ND rats (Table 2).
4.2. Skeletal and visceral examination
There were not skeletal and visceral anomalies in the
f e t u s e s  f r o m  r a t s  o f  t h e  t w o  e x pe r i m e n t a l  g r o u p s  p r e -
sented with statistical differences (p > 0.05) (Table 3 and
4, respectively).
Discussion
The mild diabetes model in pregnant female rats using
induction with STZ at two different timepoints led to
increased glycemia at day 14 of pregnancy. This discrete
increase of glycemia at day 14 of pregnancy is compatible
to the increase found in the DMG in women. The eleva-
tion of maternal glycemia in the third week of pregnancy
may correspond clinically to the 24th and 26th weeks of
gestation in women when the diagnosis of DMG, charac-
terized by glucose intolerance is made [1,2]. This finding
evidences that the female rats of the STZ group devel-
oped, during the pregnancy period, diabetes that simu-
lates human DMG.
It was observed that the plasma insulin concentrations
between the two groups were similar at the end of the
pregnancy, corroborating with results found by Triadou
and colleagues [24].
In the present study, the female rats of the STZ group
presented with a reduction in the number of corpora
lutea, evidencing a reduction in the number of oocytes
liberated during the ovulation process. Similarly, there
fewer fertilized mature oocytes and implanted embryos
as a function of the altered intrauterine environment in
those female rats. Due to the alterations in the number of
corpora lutea and implantations in the female rats of the
STZ group there was a significant increase in the rates of
pre and post-implantation losses, respectively. However,
the embryos that were implanted did develop, as there
was not an alteration in the number of live fetuses.
Figure 3 Fetal weight classification of offspring born to mild dia-
betic (STZ) and non-diabetic (ND) rats. Fetal weight classification is 
defined as small for pregnancy age (SPA), appropriate for pregnancy 
age (APA) or large for pregnancy age (LPA). *p < 0.05 -Chi Square Test.
Figure 2 Glycemia of dams throughout the pregnancy. Glycemia 
were taken on days 0, 7, 14 and 21 of pregnancy from mild diabetic 
(STZ) and non-diabetic (ND) rats. Data are reported as mean ± standard 
deviation. *p < 0.05 - Student-Newman-Keuls Test.Saito et al. Diabetology & Metabolic Syndrome 2010, 2:26
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In uncontrolled human diabetes, there is evidence of an
increased rate of intrauterine deaths and abortions, and
in rats with severe diabetes, there is an increase in embry-
onic deaths [17,42-44]. DMG is associated with increased
morbidity (hypoglycemia, hypocalcemia, polycythemia,
hyperbilirubinemia, and macrosomia) and fetal mortality
[45], and the pregnant diabetic is more prone to exhibit
an increased incidence of miscarriage compared to non-
diabetic pregnant women [46].
The rats that received the β-cytotoxic agent in the neo-
natal period and at day 7 of pregnancy began the gesta-
tional period with reduced weight because of metabolic
changes caused since the induction of diabetes in the
neonatal period. Besides, our results showed that rats of
the STZ group showed no difference in mean fetal
weight. However, the analysis of the classification of the
weights of fetuses from STZ rats showed increased rates
of fetuses classified as small for pregnancy age (SPA) and
reduced rates of fetuses classified as appropriate for ges-
tational age (APA), even dams with glucose not exceeding
300 mg/dL (severe diabetes). Given that there was
another application of streptozotocin at day 7 of preg-
nancy and this is the organogenesis period, the hypogly-
cemia may have altered the growth and development of
fetuses from STZ rats. Furthermore, the method of
administration of diabetogenic drugs during pregnancy
in rats may have also interfere with the viability of the
fetuses, as the route of administration was intraperito-
neal.
STZ rats presented SPA fetuses. These data are not
consistent with the literature data, which shows that
maternal hyperglycemia less than 300 mg/dL causes fetal
hyperglycemia, stimulating pancreatic beta cells to
secrete more insulin, leading to excessive growth of the
fetus or macrosomia [15,47]. The intrauterine growth
r e s t r i c t i o n  ( f e t u s e s  c l a s s i f i e d  a s  S P A )  m a y  a l s o  b e
explained by maternal hyperglycemia above 300 mg/dL
(severe diabetes), which leads to depletion of functional
fetal pancreas with reduced insulin production, causing
an insult to fetal growth [15,48], and thus a higher pro-
portion of fetuses SPA. However, this explanation is not
valid for the type of induction used in our study, as the
Table 1: Reproductive performance and maternal insulin from mild diabetic (STZ) and non-diabetic (ND) rats.
Group ND STZ
Number of used rats 15 67
Number of pregnant rats at term 15 28
Number of corpora lutea 14.00 ± 1.60 10.30 ± 2.00*
Number of implantations 13.23 ± 1.30 7.31 ± 3.10*
Number of live fetuses 161 108
Pre-implantation loss (%) 5.14 22.00*
Post-implantation loss (%) 5.77 26.10*
Fetal weight (g) 5.27 ± 0.28 4.94 ± 0.62
Maternal insulin (μg/L) 0.56 ± 0.51 0.78 ± 0.62
Data are reported as mean ± standard deviation
*p < 0.05 - Student-Newman-Keuls Test
Table 2: Ossification sites of fetuses from mild diabetic (STZ) and non-diabetic (ND) rats.
Ossification Sites ND STZ
Anterior phalange 3.99 ± 0.04 2.65 ± 1.20*
Metacarpus 4.00 ± 0.00 3.86 ± 0.31
Posterior phalange 2.58 ± 1.09 0.78 ± 1.60*
Metatarsus 4.98 ± 0.05 4.35 ± 0.43*
Caudal vertebrae 4.39 ± 0.81 4.24 ± 1.42
Sternebrae 6.00 ± 0.00 5.95 ± 0.12
Total 25.93 ± 1.50 21.82 ± 4.39*
Data are reported as mean ± standard deviation
*p < 0.05 - Student-Newman-Keuls TestSaito et al. Diabetology & Metabolic Syndrome 2010, 2:26
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rats did not show at any time of pregnancy the high blood
glucose levels that characterized severe diabetes.
Fetal growth is a complex process that depends on the
genotype and epigenotype of the fetus, maternal nutri-
tion, the availability of nutrients and oxygen to the fetus,
intrauterine insults, and a variety of growth factor and
proteins of maternal, fetal and placental origin [49]. Dur-
ing the first trimester of pregnancy, embryonic growth
might be controlled at the level of the individual organs
by nutrient supply and by locally active growth factors.
Later, fetal growth depends essentially upon maternal-
placental cooperation in delivering nutrients to the fetus.
Therefore the major hole of hormones in fetal growth is
to mediate utilization of available substrate. Fetal growth
seems to be regulated by fetal insulin, insulin-like growth
factor (IGF-1) and IGF-2, while growth hormone (GH)
has only a secondary hole to play [50]. During pregnancy,
placental growth hormone (PGH) is the prime regulator
of maternal serum IGF-1. The alterations in the maternal
GH/IGF axis may lead to permanent pathological fetal
programming of the IGF axis [50], causing late conse-
quences of poor fetal environment reflected in intrauter-
ine growth restriction, as confirmed by our results.
Table 3: Frequency of skeletal anomaly of fetuses from mild diabetic (STZ) and non- diabetic (ND)rats.
Skeletal Anomaly (%) ND
(n = 81 fetuses)
STZ
(n= 41 fetuses)
Number of fetal skeletal anomalies/dams 10/15 17/11
Abnormally shaped sternebrae 2/81 (2.47) 9/41 (21.95)
Absent sternebrae 0/81 (0.00) 1/41 (2.43)
Incomplete ossification of sternebrae 0/81 (0.00) 3/41 (7.32)
Bipartite cervical nuclei 3/81 (3.70) 0/41 (0.00)
Incomplete ossification of cervical nuclei 5/81 (6.17) 0/41 (0.00)
Non-ossified sacral vertebrae 0/81 (0.00) 1/41 (2.43)
Non-ossified caudal vertebrae 0/81 (0.00) 3/41 (7.32)
p > 0.05 - non-significant
Table 4: Frequency of visceral anomaly of fetuses from mild diabetic (STZ) and non-diabetic (ND) rats.
Visceral Anomaly (%) ND
(n = 74 fetuses)
STZ
(n = 37 fetuses)
Number of fetal visceral anomalies/dams 86/15 27/12
Distended bladder 1/74 (1.35) 2/37 (5.40)
Dilated renal papilla 0/74 (0.00) 4/37 (10.81)
Absent renal papilla 0/74 (0.00) 1/37 (2.70)
Small renal papilla 0/74 (0.00) 1/37(2.70)
Ectopic kidney 36/74 (48.65) 4/37 (10.81)
Hydroureter 19/74 (25.70) 5/37 (13.51)
Hydronephrosis 1/74 (1.35) 0/37 (0.00)
Crystalline altered 0/74 (0.00) 1/37 (2.70)
Enlarged nasal cavity 9/74 (12.16) 0/37 (0.00)
Abnormal palate 2/74 (2.70) 1/37 (2.70)
Dilated trachea 5/74 (6.76) 4/37 (10.81)
Dilated esophagus 1/74 (1.35) 3/37 (8.11)
Dilated pulmonary trunk 9/74 (12.16) 0/37 (0.00)
Dilated cerebral ventricle 2/74 (2.70) 1/37 (2.70)
Small testis 1/74 (1.35) 0/37 (0.00)
p > 0.05 - non-significantSaito et al. Diabetology & Metabolic Syndrome 2010, 2:26
http://www.dmsjournal.com/content/2/1/26
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Although the fetuses of ND rats have shown high fre-
quencies of abnormalities, in visceral analysis, in the
comparison between the two groups these values did not
differ significantly. The enlarged ureter is an alteration
easily recognized by the format in "S", it can be associated
or not to the congenital hydronephrosis or any pelvic
alterations and, usually, it is transitory in rodents [51].
However, the high rate of ectopic kidney in control rats is
unclear. The literature evidences that 10 to 20% of the
newly born of control female rats (non-diabetic) present
that type of smaller visceral malformation. This result
seems not to be exclusive of the diabetes [52-54] and does
not exist definition about the critical period of the preg-
nancy of female rats for the development of these struc-
tures. Therefore, the mild diabetes induced in the
neonatal period and during pregnancy showed no terato-
genic effect on fetuses.
Conclusion
The mild diabetes led a negative impact on maternal
reproductive performance, as evidenced by the increase
in the percentages of embryofetal loss and changes in
embryo-fetal development confirmed by the presence of
fetuses small for gestational age of pregnancy (intrauter-
ine growth restriction). Our study also characterized the
presence of a smaller number of rats with hyperglycemia
in pregnancy to term and their descendants did not have
macrosomia, but showed retardation of fetal develop-
ment as confirmed by decreased number of ossification
sites.
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